NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards